Breast cancer (early) - docetaxel
Docetaxel for the adjuvant treatment of early node-positive breast cancer
| Guidance type: Technology appraisal |
| Date issued: September 2006 |
We will consult on our review plans for this guidance in June 2007. |
| Reference: TA109 |
SummaryDocetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the public
Background information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below: |
| Top |
